Moderna stock surges as melanoma vaccine trial shows landmark moment

Moderna and Merck announced study results that reflect a "landmark moment" in treatment for one of the deadliest forms of skin cancer.

Moderna's Melanoma Result Landed On A Market Positioned The Other Way

The trial met both endpoints in the readout, removing the inconclusive outcome management itself had flagged, and short sellers in the stock took a record single-session loss.

COVID-era juggernaut Moderna spikes 177% after successful late-stage trial for melanoma drug

Moderna has been looking for its next blockbuster drug after a wildly successful COVID era.

Moderna's cancer vaccine hits key goal in melanoma trial with NYU Langone link

Moderna shares jumped this week after the company announced encouraging results from a late-stage melanoma trial.

Moderna oncology platform draws Street value after melanoma trial win

Moderna Inc (NASDAQ:MRNA, XETRA:0QF)'s melanoma trial success is prompting Wall Street to assign new platform value to the company's oncology pipeline, Jefferies said, as investors look beyond its COVID-dependent revenue base.
BioSpace

Merck’s Moderna-partnered vaccine success clears view of post-Keytruda future

Investors had been pessimistic about the probability of success for the personalized cancer vaccine intismeran autogene, so the Phase 3 win was a welcome surprise.